These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 9196442

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis.
    Nasreen N, Mohammed KA, Hardwick J, Van Horn RD, Sanders K, Kathuria H, Loghmani F, Antony VB.
    Oncol Res; 2002; 13(2):71-8. PubMed ID: 12392154
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
    Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, Sliwa M, Franciszkiewicz K, Chouaib S, Kaminska B.
    Oncogene; 2008 Feb 07; 27(7):918-30. PubMed ID: 17684491
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep 07; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

  • 28. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas.
    Rao CN, Lakka SS, Kin Y, Konduri SD, Fuller GN, Mohanam S, Rao JS.
    Clin Cancer Res; 2001 Mar 07; 7(3):570-6. PubMed ID: 11297250
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Hyaluronan-CD44 promotes phospholipase C-mediated Ca2+ signaling and cisplatin resistance in head and neck cancer.
    Wang SJ, Bourguignon LY.
    Arch Otolaryngol Head Neck Surg; 2006 Jan 07; 132(1):19-24. PubMed ID: 16415424
    [Abstract] [Full Text] [Related]

  • 32. Hyaluronic acid inhibits adhesion of hepatic stellate cells in spite of its stimulation of DNA synthesis.
    Cho MK, Lee GH, Park EY, Kim SG.
    Tissue Cell; 2004 Oct 07; 36(5):293-305. PubMed ID: 15385147
    [Abstract] [Full Text] [Related]

  • 33. Exogenous hyaluronic acid enhances porcine parthenogenetic embryo development in vitro possibly mediated by CD44.
    Toyokawa K, Harayama H, Miyake M.
    Theriogenology; 2005 Jul 15; 64(2):378-92. PubMed ID: 15955360
    [Abstract] [Full Text] [Related]

  • 34. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis.
    Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, Rao JS.
    Oncogene; 2004 Jun 10; 23(27):4681-9. PubMed ID: 15122332
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro.
    Koochekpour S, Pilkington GJ, Merzak A.
    Int J Cancer; 1995 Nov 03; 63(3):450-4. PubMed ID: 7591247
    [Abstract] [Full Text] [Related]

  • 39. Regulation of glioma cell phenotype in 3D matrices by hyaluronic acid.
    Pedron S, Becka E, Harley BA.
    Biomaterials; 2013 Oct 03; 34(30):7408-17. PubMed ID: 23827186
    [Abstract] [Full Text] [Related]

  • 40. Comparison of in vitro invasiveness of human breast carcinoma in early or late stage with their malignancy in vivo.
    Le Marer N, Bruyneel E.
    Anticancer Res; 1996 Oct 03; 16(5A):2767-72. PubMed ID: 8917384
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.